[HTML][HTML] Efficacy and safety of iptacopan in patients with C3 glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney international …, 2023 - Elsevier
Introduction Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero… - Kidney …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
[HTML][HTML] Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney International …, 2023 - ncbi.nlm.nih.gov
Methods In this phase 2, multicenter, open-label, single-arm, nonrandomized study, adults
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney International …, 2023 - europepmc.org
Methods In this phase 2, multicenter, open-label, single-arm, nonrandomized study, adults
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
[HTML][HTML] Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney International …, 2023 - kireports.org
Introduction Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney international …, 2023 - iro.uiowa.edu
Abstract Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras… - Kidney International …, 2023 - eprints.ncl.ac.uk
Abstract© 2023 International Society of NephrologyIntroduction: Complement 3
glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of …
glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of …
[引用][C] Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
E Wong, C Nester, T Cavero… - Kidney …, 2023 - produccioncientifica.ucm.es
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
E Wong, C Nester, T Cavero, A Karras… - Kidney International …, 2023 - europepmc.org
Methods In this phase 2, multicenter, open-label, single-arm, nonrandomized study, adults
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with …
Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy
E Wong, C Nester, T Cavero, A Karras, M Le Quintrec… - kireports.org
Patients (aged≥ 18 years, body mass index 18–38 kg/m2 with systolic and diastolic blood
pressure of 80–170 mm Hg and 50–105 mm Hg, respectively) with complement 3 …
pressure of 80–170 mm Hg and 50–105 mm Hg, respectively) with complement 3 …